REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,674,387 | -79.1% | 16,422 | -81.3% | 0.00% | -83.3% |
| Q1 2023 | $8,001,596 | +3021.3% | 88,007 | +1204.2% | 0.01% | – |
| Q4 2022 | $256,357 | -2.2% | 6,748 | -35.3% | 0.00% | – |
| Q3 2022 | $262,000 | -27.4% | 10,425 | -12.4% | 0.00% | – |
| Q2 2022 | $361,000 | +29.9% | 11,894 | +40.6% | 0.00% | – |
| Q1 2022 | $278,000 | -9.4% | 8,462 | -27.3% | 0.00% | – |
| Q4 2021 | $307,000 | -88.8% | 11,637 | -57.1% | 0.00% | -100.0% |
| Q3 2021 | $2,731,000 | +2.9% | 27,146 | +44.8% | 0.00% | 0.0% |
| Q2 2021 | $2,653,000 | +39.5% | 18,743 | -1.8% | 0.00% | +100.0% |
| Q1 2021 | $1,902,000 | -3.0% | 19,080 | +20.4% | 0.00% | 0.0% |
| Q4 2020 | $1,960,000 | +21.7% | 15,849 | -4.1% | 0.00% | 0.0% |
| Q3 2020 | $1,610,000 | -59.4% | 16,529 | -35.0% | 0.00% | -66.7% |
| Q2 2020 | $3,969,000 | +17.3% | 25,444 | +8.5% | 0.00% | 0.0% |
| Q1 2020 | $3,385,000 | -16.2% | 23,453 | +18.7% | 0.00% | 0.0% |
| Q4 2019 | $4,038,000 | +147.3% | 19,752 | -2.9% | 0.00% | +200.0% |
| Q3 2019 | $1,633,000 | +9.2% | 20,332 | +28.2% | 0.00% | 0.0% |
| Q2 2019 | $1,495,000 | +62.3% | 15,854 | +47.2% | 0.00% | 0.0% |
| Q1 2019 | $921,000 | +90.3% | 10,769 | +24.8% | 0.00% | – |
| Q4 2018 | $484,000 | -24.4% | 8,628 | +10.2% | 0.00% | -100.0% |
| Q3 2018 | $640,000 | +1291.3% | 7,831 | +491.9% | 0.00% | – |
| Q2 2018 | $46,000 | -11.5% | 1,323 | -48.1% | 0.00% | – |
| Q1 2018 | $52,000 | +48.6% | 2,550 | +108.8% | 0.00% | – |
| Q4 2017 | $35,000 | +9.4% | 1,221 | +17.4% | 0.00% | – |
| Q3 2017 | $32,000 | +966.7% | 1,040 | +1042.9% | 0.00% | – |
| Q2 2017 | $3,000 | -82.4% | 91 | -88.0% | 0.00% | – |
| Q1 2017 | $17,000 | -86.4% | 759 | -86.7% | 0.00% | – |
| Q4 2016 | $125,000 | +941.7% | 5,721 | +1127.7% | 0.00% | – |
| Q3 2016 | $12,000 | +9.1% | 466 | -18.5% | 0.00% | – |
| Q2 2016 | $11,000 | – | 572 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |